Connect with us

U.S. urges all WTO members to support intellectual property waiver for COVID-19 vaccines

HBS Reporting

U.S. urges all WTO members to support intellectual property waiver for COVID-19 vaccines

U.S. urges all WTO members to support intellectual property waiver for COVID-19 vaccines

WASHINGTON, Oct 21 (Reuters) – The White House on Thursday called on all World Trade Organization members to support an intellectual property waiver for COVID-19 vaccines.

“We … need every WTO member to step up as well and support an intellectual property waiver, and every company must act ambitiously and urgently to expand manufacturing now,” White House spokesperson Karine Jean-Pierre told reporters.

A year after South Africa and India introduced a proposal to temporarily waive intellectual property rights on COVID-19 vaccines and therapies at the WTO, negotiations have failed to make any progress. More than 100 countries backing the waiver say it will help save lives by allowing developing countries to produce COVID-19 vaccines, but the European Union and several countries, including Switzerland, remain opposed.

U.S. President Joe Biden reversed the previous U.S. position to back the proposal in May, but a breakthrough has so far failed to materialize.

WTO Director-General Ngozi Okonjo-Iweala last week conceded the formal negotiations about a temporary waiver were “stuck,” but said she believed informal talks were intensifying.

Okonjo-Iweala told a Washington think tank she believed that WTO members could “find a pragmatic compromise on the IP waiver” that would ensure equitable access to vaccines, while preserving incentives for research and innovation.

An EU official described “intense talks” with South Africa about how to boost the availability of vaccines to developing countries, potentially breaking the deadlock. The WTO wants to reach an agreement on the global response to the pandemic at its ministerial conference in Geneva from Nov. 30 to Dec. 3.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

More in HBS Reporting